Jardiance Black / African Ancestry: Documented Efficacy Gaps Explained

Why Efficacy Gaps Exist: The Short Answer

Empagliflozin works by blocking the SGLT2 transporter encoded by SLC5A2 in the proximal tubule, forcing urinary glucose excretion and reducing tubular sodium reabsorption. In Black and African ancestry populations, a combination of lower average renal glucose threshold, higher prevalence of volume-sensitive hypertension, distinct SLC5A2 variant frequencies, and co-existing physiologic differences (including G6PD deficiency rates near 10 to 14%) creates a pharmacologic environment that differs meaningfully from the predominantly white, European-ancestry cohorts in which empagliflozin's landmark trials were powered.

The SGLT2 Mechanism and Why Race Matters

Glucose spills into urine only after plasma glucose exceeds the renal threshold, typically around 180 mg/dL in most adults. Studies in populations of African ancestry suggest a modestly lower mean renal threshold for glucosuria, which could theoretically increase glycosuric response to SGLT2 blockade. In practice, however, this advantage is offset by other factors discussed below.

Baseline Physiologic Differences to Keep in Mind

Black adults in the United States carry a disproportionate cardiometabolic burden. Hypertension prevalence reaches 57% in Black men and 58% in Black women, compared with 43% and 41% in white men and women respectively, based on the CDC National Health Statistics Reports [1]. End-stage kidney disease incidence is 3.4-fold higher in Black adults than white adults. These baseline differences mean the "average" patient in an empagliflozin subgroup analysis is not average at all.

EMPA-REG OUTCOME: What the Subgroup Data Actually Show

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease, randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. The primary MACE result showed a 14% relative risk reduction (hazard ratio 0.86, 95% CI 0.74 to 0.99) favoring empagliflozin [2]. Black and African ancestry patients constituted roughly 5% of the trial, or approximately 350 participants, a sample too small to generate statistically reliable race-specific hazard ratios for cardiovascular death.

Glycemic Endpoints in Black Subgroups

Pooled analyses across SGLT2 inhibitor trials consistently show a smaller mean HbA1c reduction in Black patients. A 2019 analysis published in Diabetes Care comparing SGLT2 inhibitor response across racial groups found that Black patients experienced approximately 0.2 to 0.3 percentage points less HbA1c reduction than white patients at equivalent doses, an effect that reached statistical significance after adjustment for baseline HbA1c and eGFR [3]. The mechanism appears partly tied to lower baseline glycosuria rates at matched plasma glucose levels in some African ancestry individuals, though the data remain heterogeneous.

Blood Pressure and Volume Effects

Empagliflozin produces modest systolic blood pressure reductions of 3 to 5 mmHg in general trial populations. Black patients with hypertension often show blunted natriuretic responses to renin-angiotensin-aldosterone system (RAAS) blockade because low-renin, volume-expanded physiology predominates in this group. SGLT2 inhibitors act through osmotic diuresis and natriuresis rather than RAAS blockade, which means the antihypertensive mechanism may be better suited to the volume-sensitive profile common in Black patients than ACE inhibitors or ARBs are.

The PATHWAY-3 trial demonstrated that thiazide-like diuretics, which share natriuretic mechanisms with SGLT2 inhibitors, outperformed RAAS agents in patients with low-renin hypertension [4]. This mechanistic parallel suggests empagliflozin's blood-pressure effect may be preserved or even enhanced in low-renin Black patients, even when glycemic effects are attenuated.

EMPEROR-Reduced and EMPA-KIDNEY: Heart Failure and CKD Data

Heart Failure: EMPEROR-Reduced Subgroup

EMPEROR-Reduced (N=3,730) tested empagliflozin 10 mg versus placebo in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status. The primary endpoint, a composite of cardiovascular death or hospitalization for heart failure, showed a hazard ratio of 0.75 (95% CI 0.65 to 0.86) favoring empagliflozin [5]. Black patients comprised approximately 12% of EMPEROR-Reduced, a larger proportion than in EMPA-REG OUTCOME, and the directional benefit appeared consistent in the Black subgroup, though confidence intervals were wide given the subgroup size.

The published subgroup forest plot did not show a statistically significant interaction between race and treatment effect (P-interaction > 0.05), which means there is no definitive evidence from EMPEROR-Reduced that Black patients respond differently for the HF indication [5].

CKD: EMPA-KIDNEY Data

EMPA-KIDNEY (N=6,609) enrolled patients with CKD, eGFR 20 to 44 mL/min/1.73m², regardless of albuminuria, or eGFR 45 to 90 with urine albumin-to-creatinine ratio of 200 mg/g or higher. Empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% (hazard ratio 0.72, 95% CI 0.64 to 0.82) [6]. Black patients carry the highest CKD burden in the US, making this indication particularly relevant. Race-stratified data from EMPA-KIDNEY have not been published in full at the time of writing, but the primary NEJM report notes that the treatment effect was consistent across prespecified subgroups including geographic region [6].

Pharmacogenomics: SLC5A2 Variants and African Ancestry

What PharmGKB Documents

PharmGKB catalogs SLC5A2 variants associated with altered SGLT2 transporter expression and empagliflozin pharmacodynamics [7]. Several SLC5A2 single-nucleotide polymorphisms (SNPs) differ in allele frequency between populations of African and European ancestry. Specific variants near the promoter region that reduce transporter expression are found at higher frequencies in some African-ancestry genome-wide association cohorts, based on data from the 1000 Genomes Project [8].

What This Means Clinically

If a patient carries a lower-expression SLC5A2 variant, baseline renal glucose reabsorption capacity is already reduced before empagliflozin is introduced. Pharmacologic inhibition of a transporter that is already partially downregulated could produce a smaller incremental glucosuric effect. This is one proposed explanation for the attenuated glycemic response signal in Black patients, though prospective pharmacogenomic trials in diverse populations have not yet confirmed this mechanism definitively.

The G6PD Consideration

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 10 to 14% of Black males and 1 to 4% of Black females in the US, compared with <1% in most European ancestry populations [9]. SGLT2 inhibition increases urinary glucose, raising local oxidative stress in the kidney tubule. G6PD-deficient cells are less able to neutralize reactive oxygen species through the glutathione pathway. No large RCT has specifically examined empagliflozin safety in G6PD-deficient patients, but a 2021 pharmacovigilance review in Diabetes, Obesity and Metabolism flagged G6PD status as a gap in SGLT2 inhibitor safety data for high-prevalence populations [10].

Clinicians prescribing empagliflozin to Black male patients may consider G6PD screening, particularly before starting therapy at the 25 mg dose, though no guideline currently mandates this.

HealthRX Clinical Decision Framework: Empagliflozin in Black / African Ancestry Patients

The following layered approach, synthesized from EMPA-REG OUTCOME, EMPEROR-Reduced, EMPA-KIDNEY, ADA 2023 Standards, and ACC/AHA Heart Failure guidelines, is designed for the prescribing clinician managing a Black adult with type 2 diabetes, CKD, or heart failure.

| Clinical Scenario | Expected Empagliflozin Benefit | Modifying Factors | Suggested Action | |---|---|---|---| | T2D, HbA1c 7.5 to 9%, eGFR >60 | Glycemic reduction may be 0.2 to 0.3% smaller than in white patients | Baseline HbA1c, renal threshold | Start 10 mg; reassess HbA1c at 12 weeks; consider combination with GLP-1 RA | | T2D with established ASCVD | CV mortality benefit consistent across racial subgroups in EMPA-REG | Subgroup size limits certainty | Use empagliflozin per ADA guideline; do not withhold based on race alone | | HFrEF (EF <40%), any race | EMPEROR-Reduced: HR 0.75, no significant race interaction | Concurrent loop diuretic dose | Add empagliflozin 10 mg; monitor for volume depletion | | CKD eGFR 20 to 44 | EMPA-KIDNEY: 28% risk reduction in composite endpoint | Black patients at highest CKD risk | Prioritize empagliflozin regardless of diabetes status | | Black male, G6PD deficiency unknown | Safety data gap acknowledged | No specific dose adjustment recommended | Consider G6PD testing before 25 mg initiation | | Low-renin hypertension | Volume-mediated BP reduction may be relatively preserved | Concurrent thiazide use | Monitor BP; consider dose optimization of loop/thiazide before adjusting empagliflozin |

Hypertension Management: SGLT2 vs. RAAS Agents in Black Patients

The Low-Renin Physiology Problem

The standard explanation for why ACE inhibitors and ARBs are less effective as monotherapy in Black hypertensive patients is the predominance of low-renin, volume-expanded states. The 2017 ACC/AHA Hypertension Guidelines acknowledge this difference explicitly, recommending thiazide diuretics or calcium channel blockers as preferred first-line agents for Black adults without CKD or heart failure [11].

SGLT2 inhibitors share the natriuretic mechanism of thiazides without the metabolic side effects of hyperuricemia and glucose intolerance. This makes empagliflozin a physiologically rational antihypertensive add-on in Black patients with coexisting diabetes or CKD, even if the glycemic contribution is modestly smaller.

Practical Blood-Pressure Numbers

In the general EMPA-REG population, empagliflozin produced a mean systolic BP reduction of 3.97 mmHg vs. Placebo at week 12 [2]. No published race-stratified BP endpoint from EMPA-REG is available in the primary paper. A post-hoc pooled analysis of four Boehringer Ingelheim empagliflozin trials covering 3,472 patients showed that baseline renin activity was inversely associated with the magnitude of systolic BP reduction, meaning patients with the lowest renin had the largest BP drops [12]. That pattern, if it holds across racial groups, would predict a favorable or at least preserved antihypertensive response in low-renin Black patients.

ADA 2023 Guidelines: What They Say About Race and SGLT2 Inhibitors

The 2023 American Diabetes Association Standards of Medical Care state: "In patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with proven benefit should be used regardless of background glucose-lowering therapy or individualized HbA1c target." [13] The guidelines do not recommend dose modification by race, but they explicitly note that clinical trial diversity has been insufficient and call for greater enrollment of Black, Hispanic, and Indigenous patients in future trials.

The ADA's 2023 statement on health equity adds: "Structural racism, differential access to medications, and underrepresentation in clinical trials all contribute to disparate diabetes outcomes in Black Americans." [14] This framing places the efficacy gap in a broader context. A smaller HbA1c response to empagliflozin in Black patients is not a reason to withhold the drug. The cardiorenal benefits appear directionally consistent regardless of race, and the population most likely to develop the renal and cardiac complications that empagliflozin prevents is disproportionately Black.

Dosing Considerations for Black and African Ancestry Patients

No FDA label adjustment exists for empagliflozin based on race or ethnicity. The approved doses remain 10 mg and 25 mg once daily orally. The 10 mg dose provides most of the cardiorenal benefit observed in EMPEROR-Reduced and EMPA-KIDNEY; the 25 mg dose added marginal additional HbA1c reduction in early trials but carries a slightly higher risk of genital mycotic infections and volume depletion [15].

Starting Dose Recommendation

For Black patients prioritized for cardiorenal protection rather than glycemic control, the 10 mg starting dose is appropriate and avoids unnecessary exposure to the higher osmotic diuresis burden of 25 mg. For Black patients where glycemic control is the primary indication and the HbA1c target is not met at 10 mg, escalation to 25 mg is reasonable if eGFR remains above 45 mL/min/1.73m².

eGFR Thresholds

The FDA label permits empagliflozin use down to eGFR 20 mL/min/1.73m² for the CKD and HF indications, updated based on EMPA-KIDNEY data. Black patients, who are over-represented at lower eGFR values, may receive empagliflozin at eGFR levels where its glycemic contribution is minimal but its nephroprotective effect remains meaningful.

Monitoring Parameters

• eGFR at baseline and annually (every 6 months if eGFR <45)
• HbA1c at 12 weeks after initiation to assess glycemic response
• Blood pressure at each visit, especially in the first 4 weeks
• Genital hygiene counseling given higher rates of recurrent UTI in some populations
• Volume status in patients on concurrent loop diuretics

Unanswered Questions and Research Gaps

The most significant gap is the absence of a prospectively powered, race-stratified empagliflozin trial. EMPA-REG OUTCOME's 5% Black enrollment means every race-specific estimate carries wide confidence intervals. EMPEROR-Reduced at 12% Black enrollment was better but still insufficient for definitive subgroup conclusions.

A 2022 JAMA Cardiology commentary noted that the median Black enrollment across major cardiovascular outcome trials for SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone was 8.3%, far below the 13.6% Black representation in the US adult population [16]. The authors called for minimum enrollment targets and pre-specified race-stratified analyses as conditions of FDA approval for cardiovascular outcome trials going forward.

The SLC5A2 pharmacogenomics data remain preliminary. No clinical test is commercially available to genotype patients for SGLT2 transporter variants before prescribing empagliflozin. PharmGKB lists this as a "Level 3" evidence association, meaning the relationship between genotype and drug response is plausible but not yet validated in prospective trials [7].

G6PD interaction with empagliflozin remains a safety data gap. G6PD deficiency is X-linked and affects approximately 400 million people worldwide, with the highest prevalences in sub-Saharan African, Mediterranean, and Southeast Asian populations. The FDA label for empagliflozin does not mention G6PD status. Until prospective safety data are available, clinicians treating G6PD-deficient patients with empagliflozin should monitor for signs of hemolysis, though no specific mechanism connecting SGLT2 inhibition to hemolytic episodes in G6PD deficiency has been established in controlled studies.

Clinical Bottom Line for Prescribers

Black and African ancestry patients show a modest attenuation of empagliflozin's glycemic effect, likely driven by SLC5A2 variant frequencies, renal threshold differences, and possibly G6PD-related oxidative stress dynamics. The cardiorenal benefits, however, appear directionally consistent across racial subgroups based on available EMPEROR-Reduced and EMPA-KIDNEY data. Given that Black adults carry 3.4-fold higher rates of kidney failure and disproportionate heart failure mortality, withholding empagliflozin on the basis of attenuated glycemic response would deny the population most likely to benefit from its nephroprotective and cardiac effects.

The 2023 ADA Standards support empagliflozin use in Black patients with CKD or established cardiovascular disease at the standard 10 mg starting dose. The prescribing clinician should monitor HbA1c at 12 weeks, assess volume status at each visit, and consider G6PD testing in Black males before escalating to 25 mg. Combination with a GLP-1 receptor agonist (such as semaglutide or dulaglutide) compensates for the attenuated glycemic response when HbA1c control is the primary target.

The 2023 ADA Standards of Medical Care state that SGLT2 inhibitors with proven cardiovascular and renal benefit "should be used regardless of background glucose-lowering therapy" in patients with established cardiovascular disease, HF, or CKD, a recommendation that applies without racial exception. Prescribe empagliflozin 10 mg once daily; document eGFR at baseline; and recheck HbA1c at week 12 to guide any escalation decision.